Translational Research in Gastrointestinal Disorders (TARGID), Catholic University Leuven (KUL), Leuven, Belgium; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium; Department of Gastroenterology, OLV Hospitals Aalst/Asse/Ninove, Belgium.
Department of Gastroenterology, OLV Hospitals Aalst/Asse/Ninove, Belgium; Department of Gastroenterology, UZ Gent, Belgium; Department of Gastroenterology, AZ Glorieux, Ronse, Belgium.
Gastrointest Endosc. 2018 Mar;87(3):705-713.e2. doi: 10.1016/j.gie.2017.05.032. Epub 2017 Jun 1.
Self-expandable metal stents are used increasingly in the treatment of obstructing colorectal cancer (CRC). Although endoscopic colon stenting is widely accepted in palliation, disagreement exists about its role in a curative setting. This study aims to describe long-term survival data in a large patient group treated with colon stenting as a bridge to surgery for CRC.
This prospective study included 97 patients who presented in a Belgian hospital between 1998 and 2013 with obstructing, although potentially curable, CRC. All patients underwent endoscopic stenting as a bridge to surgery. Procedure-related adverse events and long-term follow-up data were retrospectively collected and compared with the CRC mortality in Belgium in the same time span.
Overall survival in this observational cohort did not differ significantly from survival in all Belgian patients with CRC in the same period (P = .14). One-year, 5-year, and 10-year survival rates were similar in both groups (95.9% vs 79.0%; 54.7% vs 51.2%; 41.0% vs 35.6%, respectively). The technical success rate was 94.8%. Seventy-three patients did not experience any adverse event. Stent migration occurred in 9 patients, whereas micro-perforations and macro-perforations were observed in 14 patients, without influence on survival. Incidence rates of peritoneal metastases did not differ between patients with and without any type of perforation (22.2% vs 15.2%, respectively; P = .47). The type of stent influenced the overall adverse event risk, mainly driven by a significant increase in stent migration in case of Wallstent enteral (Boston Scientific Corporation, Natick, Mass).
Colon stenting before surgery is effective and did not worsen the survival outcome in patients with obstructing CRC who were treated with curative intent, which affirms the role for stenting as a bridge to surgery.
自膨式金属支架越来越多地用于治疗阻塞性结直肠癌(CRC)。虽然内镜结肠支架置入术在姑息治疗中被广泛接受,但在根治性治疗中的作用仍存在争议。本研究旨在描述一组接受结肠支架置入术作为结直肠癌手术桥接治疗的大患者群体的长期生存数据。
这项前瞻性研究纳入了 1998 年至 2013 年间在比利时一家医院就诊的 97 例患有阻塞性、但有潜在治愈可能的 CRC 患者。所有患者均接受内镜下支架置入术作为手术桥接治疗。回顾性收集与该操作相关的不良事件和长期随访数据,并与同期比利时 CRC 死亡率进行比较。
在该观察队列中,总生存时间与同期所有接受 CRC 治疗的比利时患者的生存时间无显著差异(P=0.14)。两组患者的 1 年、5 年和 10 年生存率相似(95.9%对 79.0%;54.7%对 51.2%;41.0%对 35.6%)。技术成功率为 94.8%。73 例患者未发生任何不良事件。9 例患者发生支架迁移,14 例患者发生微小穿孔和大穿孔,但对生存无影响。穿孔患者和无穿孔患者的腹膜转移发生率无差异(22.2%对 15.2%;P=0.47)。支架类型影响总体不良事件风险,主要是由于 Wallstent 肠内支架(波士顿科学公司,马萨诸塞州纳蒂克)的支架迁移发生率显著增加。
在以根治为目的治疗阻塞性 CRC 患者中,手术前结肠支架置入术是有效的,且未恶化患者的生存结局,证实了支架置入术作为手术桥接的作用。